WO2000013704A1 - Formulacion de acidos nucleicos y acemanano - Google Patents
Formulacion de acidos nucleicos y acemanano Download PDFInfo
- Publication number
- WO2000013704A1 WO2000013704A1 PCT/CU1999/000004 CU9900004W WO0013704A1 WO 2000013704 A1 WO2000013704 A1 WO 2000013704A1 CU 9900004 W CU9900004 W CU 9900004W WO 0013704 A1 WO0013704 A1 WO 0013704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acemannan
- formulation
- plasmid
- nucleic acids
- dna
- Prior art date
Links
- 229960005327 acemannan Drugs 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 title claims abstract description 27
- 238000009472 formulation Methods 0.000 title claims abstract description 27
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 17
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 17
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 17
- 229960005486 vaccine Drugs 0.000 claims abstract description 24
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 102000036639 antigens Human genes 0.000 claims abstract description 20
- 108091007433 antigens Proteins 0.000 claims abstract description 20
- 230000028993 immune response Effects 0.000 claims abstract description 12
- 150000002402 hexoses Chemical class 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 4
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 28
- 102000053602 DNA Human genes 0.000 description 28
- 230000004044 response Effects 0.000 description 25
- 230000003053 immunization Effects 0.000 description 16
- 238000002649 immunization Methods 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 230000002434 immunopotentiative effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229950009811 ubenimex Drugs 0.000 description 7
- 108010041986 DNA Vaccines Proteins 0.000 description 6
- 229940021995 DNA vaccine Drugs 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 229920000057 Mannan Polymers 0.000 description 3
- 208000029549 Muscle injury Diseases 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000007402 cytotoxic response Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 229940033332 HIV-1 vaccine Drugs 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- -1 acemannan polysaccharide Chemical class 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 240000007440 Agaricus campestris Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000207439 Myra Species 0.000 description 1
- VXJYUUQAFLWXPX-UHFFFAOYSA-N N'-tert-butyl-N-(tetradecylamino)propanimidamide Chemical compound CCCCCCCCCCCCCCNN=C(CC)NC(C)(C)C VXJYUUQAFLWXPX-UHFFFAOYSA-N 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108700029888 bacteria opc Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010078575 mannan receptor Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000015323 positive regulation of phagocytosis Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9906761-7A BR9906761A (pt) | 1998-09-07 | 1999-09-03 | Formulação de vacina de ácidos nucleicos e acemanano. |
AT99942707T ATE289518T1 (de) | 1998-09-07 | 1999-09-03 | Zusammensetzung von nucleinsäuren und acemannan |
US09/530,925 US6358933B1 (en) | 1998-09-07 | 1999-09-03 | Formulation of nucleic acid and acemannan |
EP99942707A EP1029549B1 (en) | 1998-09-07 | 1999-09-03 | Formulation of nucleic acids and acemannan |
CA002308444A CA2308444A1 (en) | 1998-09-07 | 1999-09-03 | Formulation of nucleic acids and acemannan |
DE69923829T DE69923829D1 (de) | 1998-09-07 | 1999-09-03 | Zusammensetzung von nucleinsäuren und acemannan |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU126/98 | 1998-09-07 | ||
CU1998126A CU22740A1 (es) | 1998-09-07 | 1998-09-07 | Formulación de ácidos nucleicos y acemanano |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000013704A1 true WO2000013704A1 (es) | 2000-03-16 |
Family
ID=5459419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU1999/000004 WO2000013704A1 (es) | 1998-09-07 | 1999-09-03 | Formulacion de acidos nucleicos y acemanano |
Country Status (10)
Country | Link |
---|---|
US (1) | US6358933B1 (es) |
EP (1) | EP1029549B1 (es) |
CN (1) | CN1287493A (es) |
AR (1) | AR020403A1 (es) |
AT (1) | ATE289518T1 (es) |
BR (1) | BR9906761A (es) |
CA (1) | CA2308444A1 (es) |
CU (1) | CU22740A1 (es) |
DE (1) | DE69923829D1 (es) |
WO (1) | WO2000013704A1 (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001032208A1 (en) * | 1999-11-03 | 2001-05-10 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
US7223739B1 (en) | 1995-06-07 | 2007-05-29 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
EP1575500A4 (en) * | 2002-07-12 | 2007-01-03 | Univ Johns Hopkins | MESOTHELIN VACCINE AND MODEL SYSTEMS |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014195A1 (en) * | 1992-01-17 | 1993-07-22 | Solvay Animal Health, Inc. | Vaccine containing acemannan as an adjuvant |
EP0619117A2 (en) * | 1988-08-05 | 1994-10-12 | Carrington Laboratories, Inc. | Use of acemannan |
-
1998
- 1998-09-07 CU CU1998126A patent/CU22740A1/es unknown
-
1999
- 1999-09-03 CN CN99801915A patent/CN1287493A/zh active Pending
- 1999-09-03 BR BR9906761-7A patent/BR9906761A/pt not_active IP Right Cessation
- 1999-09-03 US US09/530,925 patent/US6358933B1/en not_active Expired - Fee Related
- 1999-09-03 EP EP99942707A patent/EP1029549B1/en not_active Expired - Lifetime
- 1999-09-03 DE DE69923829T patent/DE69923829D1/de not_active Expired - Lifetime
- 1999-09-03 AT AT99942707T patent/ATE289518T1/de not_active IP Right Cessation
- 1999-09-03 CA CA002308444A patent/CA2308444A1/en not_active Abandoned
- 1999-09-03 WO PCT/CU1999/000004 patent/WO2000013704A1/es active IP Right Grant
- 1999-09-07 AR ARP990104496A patent/AR020403A1/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0619117A2 (en) * | 1988-08-05 | 1994-10-12 | Carrington Laboratories, Inc. | Use of acemannan |
WO1993014195A1 (en) * | 1992-01-17 | 1993-07-22 | Solvay Animal Health, Inc. | Vaccine containing acemannan as an adjuvant |
Non-Patent Citations (2)
Title |
---|
SASAKI S. ET AL: "Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 111, January 1998 (1998-01-01), pages 30 - 35, XP000867267 * |
SASAKI S. ET AL: "Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, 1997, pages 3121 - 3129, XP000867270 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7223739B1 (en) | 1995-06-07 | 2007-05-29 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
US7699801B2 (en) | 1995-06-07 | 2010-04-20 | Powderject Vaccines, Inc. | Advanced genetic vaccines |
US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
WO2001032208A1 (en) * | 1999-11-03 | 2001-05-10 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
Also Published As
Publication number | Publication date |
---|---|
EP1029549A1 (en) | 2000-08-23 |
DE69923829D1 (de) | 2005-03-31 |
AR020403A1 (es) | 2002-05-08 |
CU22740A1 (es) | 2002-02-28 |
CA2308444A1 (en) | 2000-03-16 |
CN1287493A (zh) | 2001-03-14 |
ATE289518T1 (de) | 2005-03-15 |
EP1029549B1 (en) | 2005-02-23 |
US6358933B1 (en) | 2002-03-19 |
BR9906761A (pt) | 2000-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cui | DNA vaccine | |
KR100764678B1 (ko) | 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물 | |
Audibert et al. | Adjuvants: current status, clinical perspectives and future prospects | |
US6375945B1 (en) | Adjuvant compositions for vaccines | |
McCluskie et al. | Novel adjuvant systems | |
TW200307557A (en) | Stabilized synthetic immunogen delivery systems | |
JP6792452B2 (ja) | 免疫原性化合物 | |
US20090081157A1 (en) | Immunostimulatory Combinations for Vaccine Adjuvants | |
Moingeon et al. | Delivery technologies for human vaccines | |
KR20080027973A (ko) | 보조제 배합물로서의 큐에스-21 및 아이엘-12 | |
Wierzbicki et al. | Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein | |
WO2004044155A2 (en) | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE | |
KIM et al. | Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Thl phenotype | |
Wang et al. | Innate endogenous adjuvants prime to desirable immune responses via mucosal routes | |
Garcia et al. | An updated review of ISCOMSTM and ISCOMATRIXTM vaccines | |
Raska et al. | DNA vaccines for the induction of immune responses in mucosal tissues | |
JP2010180253A (ja) | 抗原または免疫原に対する免疫応答を仕立てる方法。 | |
WO2000013704A1 (es) | Formulacion de acidos nucleicos y acemanano | |
JP2002526420A (ja) | 脊椎動物における実質的に無毒で生物学的に活性な粘膜アジュバント | |
Ott et al. | Development of vaccine adjuvants: a historical perspective | |
JP2004533431A (ja) | アジュバントとしてi型ifnを含むワクチン及びそれと関連する方法 | |
US20050148538A1 (en) | Adjuvant formulations for bacterial and virus vaccines and method of making same | |
JP6469585B2 (ja) | 単純ヘルペスウイルス2型感染を処置するための治療用ワクチン | |
EP1716866A1 (en) | Proteoliposomes and derivatives thereof as cytotoxic response-inducing adjuvants and resulting formulations | |
Morein et al. | Biological aspects and prospects for adjuvants and delivery systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99801915.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA CN US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2308444 Country of ref document: CA Ref document number: 2308444 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09530925 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999942707 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1999942707 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999942707 Country of ref document: EP |